FDA Import Refusal 799-6004838-8/21/1 — AstraZeneca Pharmaceuticals, LP
The FDA refused shipment 799-6004838-8/21/1 from AstraZeneca Pharmaceuticals, LP (United States) on March 24, 2025. The refused product falls under Drugs and Biologics — DAPAGLIFLOZIN (ANTI-DIABETIC). Cited charge: 75 This firm has 5 or more other import refusals on record.
Refusal Details
- Date
- March 24, 2025
- Country
- United States
- Product Category
- Drugs and Biologics
- Product Code
- 61PCY70 DAPAGLIFLOZIN (ANTI-DIABETIC)
- Charges
- 75